Recent Finacing
Recent Raise
Shattuck Labs develops ARC dual-function fusion proteins combining checkpoint blockade and TNFRSF agonism for oncology and autoimmune indications, with multiple candidates in or entering Phase I.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors
See the team members at Shattuck Labs.
